Alternative Names
Anti-CD23 monoclonal antibody research-grade biosimilar; Gomiliximab research-grade biosimilar; Gomiliximab (USAN) research-grade biosimilar; IDEC-152 research-grade biosimilar; Lumiliximab research-grade biosimilar; Lumiliximab (USAN/INN) research-grade biosimilar; Primatized research-grade biosimilar; PRIMATIZED anti-CD23 research-grade biosimilar; ST-152 research-grade biosimilar; FCER2 antibody; CD23A antibody; CLEC4J antibody; FCE2 antibody; IGEBF antibody;Low affinity immunoglobulin epsilon Fc receptor antibody; BLAST-2 antibody; C-type lectin domain family 4 member J antibody; Fc-epsilon-RII antibody; Immunoglobulin E-binding factor antibody; Lymphocyte IgE receptor antibody; CD antigen CD23) [Cleaved into: Low affinity immunoglobulin epsilon Fc receptor membrane-bound form; Low affinity immunoglobulin epsilon Fc receptor soluble form] antibody
Immunogen
Recombinant Human FCER2 protein
Immunogen Species
Homo sapiens (Human)
Concentration
It differs from different batches. Please contact us to confirm it.
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Notes
Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.
Usage
It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.